
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has shown a significant improvement in its operating margins, with a 910 basis points increase year-over-year in 2024, followed by an additional 950 basis points increase in the first half of 2025. The company is benefiting from a growing market, as evidenced by the 7.3% rise in the number of liver, heart, and lung transplants in the U.S. from 2023 to 2024, alongside an upward trend in its market share, which increased from 13.8% in 2023 to 20.9% in 2024. Overall, the positive trajectory in operating margins and market share suggests strong potential for earnings per share (EPS) growth moving forward.
Bears say
TransMedics Group Inc. reported product revenues of $87.7 million, which represented a year-over-year increase of 33.1% but fell approximately $1 million short of consensus estimates, contributing to a weakening market response. The company faces multiple risks including slower adoption of its Organ Care System for lung transplants, increased competition, potential changes in reimbursement that might dampen demand, and regulatory challenges that could impede growth. Furthermore, TransMedics’ shares are currently trading at a notable discount to their historical valuation metrics, indicating potential concerns about the company's future revenue growth and commercialization effectiveness.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares